Olmesartan medoxomil + Atenolol + Hydrochlorothiazide + olmesartan medoxomil + atenolol
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Essential Hypertension
Conditions
Essential Hypertension, Atherosclerotic Cardiovascular Disease
Trial Timeline
Nov 1, 2001 โ Feb 1, 2006
NCT ID
NCT00185185About Olmesartan medoxomil + Atenolol + Hydrochlorothiazide + olmesartan medoxomil + atenolol
Olmesartan medoxomil + Atenolol + Hydrochlorothiazide + olmesartan medoxomil + atenolol is a phase 3 stage product being developed by Daiichi Sankyo for Essential Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT00185185. Target conditions include Essential Hypertension, Atherosclerotic Cardiovascular Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00185185 | Phase 3 | Completed |
Competing Products
20 competing products in Essential Hypertension